Lv1
70 积分 2021-05-13 加入
153 A Retrospective Review of the Incidence and Management of Toxicities arising during Lorlatinib Treatment for Metastatic ALK gene fusion Non-Small Cell Lung Cancer (NSCLC) – Our Experience in a Mutationdriven Lung Cancer Clinic at The Clatterbridge Cancer Centre (CCC)
1个月前
已关闭
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer
1个月前
已关闭
Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis
2个月前
已完结
Amivantamab-Associated Vasculitis in a Patient with EGFR Exon 20 Insertion Non-Small Cell Lung Cancer: A Case Report
3个月前
已完结
Organising pneumonia following amivantamab treatment: a case report
3个月前
已完结
Severe Pustular Drug Eruptions From Amivantamab: A Case Series
3个月前
已完结
From the desert to the savannah, the future of combined MET-EGFR treatment
3个月前
已关闭
TROP-2–directed antibody–drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes
3个月前
已完结
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan
3个月前
已完结
SMARCA4-deficient Non-small Cell Lung Carcinoma Harboring ALK Fusion
3个月前
已完结
皖公网安备34019202002308
